Evidence map›Paper›PMID 40810753›Full record

ReviewInflammopharmacology2025

Therapeutic potential of Boswellia serrata in arthritis management: mechanistic insights into COX-2, 5-LOX, and NFĸB modulation.

Koleshwar Mahto, Omkar Kumar Kuwar, Aayushi Maloo, Abhishek Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Advances in Drug Delivery Systems for Boswellic Acids fromInternational journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Koleshwar MahtoDepartment of Physiotherapy, Mewar University, Gangrar, Chittorgarh, Rajasthan, 312901, India.
Omkar Kumar KuwarDepartment of Pharmacology, Bihar College of Pharmacy, New Bailey Road, Patna, Bihar, 801503, India. omkar.official.955@gmail.com.ORCID http://orcid.org/0009-0007-1796-4913
Aayushi MalooDepartment of Pharmacology, IPS Academy, College of Pharmacy, Knowledge Village, A.B. Road, Indore, Madhya Pradesh, 452012, India.
Abhishek KumarDepartment of Pharmacy, Mewar University, Gangrar, Chittorgarh, Rajasthan, 312901, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arthritis is a chronic inflammatory disorder characterized by joint pain, stiffness, and progressive cartilage degeneration, significantly impacting patient's quality of life. Current pharmacological treatments, including nonsteroidal anti-inflammatory drugs and corticosteroids, provide symptomatic relief but are associated with adverse effects and limited long-term efficacy. Boswellia serrata, a medicinal plant with a long history of use in traditional medicine, has gained attention for its potential in arthritis management due to its anti-inflammatory, chondroprotective, and immunomodulatory properties. The bioactive constituents, particularly boswellic acids, have been shown to inhibit primary inflammatory pathways including NFĸB, COX-2, and 5-LOX, thereby reducing inflammation and cartilage degradation. Preclinical and clinical studies suggest that Boswellia serrata alleviates pain, improves joint mobility, and slows disease progression with a favorable safety profile compared to conventional therapies. Despite these promising findings, challenges such as limited large-scale clinical trials, variability in extraction methods, and low bioavailability hinder its clinical application. Future research should focus on optimizing formulation strategies, exploring synergistic effects with existing therapies, and conducting high-quality randomized controlled trials to validate its efficacy and safety. In addition, mechanistic studies investigating its molecular targets and interactions with the gut microbiome could provide deeper insights into its therapeutic potential. This review critically evaluates the current evidence on Boswellia serrata in arthritis management, highlights existing research gaps, and discusses future directions for its clinical development. Addressing these challenges will facilitate its integration into mainstream medicine, offering a natural, safer, and potentially more effective alternative for arthritis treatment.

Indexed as

ArthritisBoswelliaPlant ExtractsAnimalsAnti-Inflammatory AgentsArachidonate 5-LipoxygenaseCyclooxygenase 2HumansNF-kappa BTriterpenesAnti-Inflammatory AgentsArachidonate 5-Lipoxygenaseboswellic acidCyclooxygenase 2NF-kappa BPlant ExtractsTriterpenes5-LOXAnti-inflammatoryArthritisBoswellia serrataBoswellic acidsCOX-2NFĸB

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.